Immunotherapeutic Vaccine as an Alternative Treatment to Overcome Drug-Resistant Ovarian Cancer
Abstract
The overall goal is to develop a multivalent vaccine that may be administered in combination with chemotherapy or targeted therapies to address platinum-resistant ovarian cancer (Ov Ca). We identified vaccine candidate epitopes over-presented in platinum resistant Ov Ca cells and initially proposed to activate cytolytic T cells (CTL) against these epitopes in vitro and to test their cytolysis of platinum resistant cells (alone and with cisplatin and dasatinib); however, repeated attempts to expand the CTL were unsuccessful. We therefore, chose two of the genes that contained representative epitopes (EDDR1 and ADAM17/TACE) and cloned them into adenoviral vectors. We demonstrated that these vectors were immunogenic and induced immune responses against EDDR1 and TACE respectively. T cella activated against these vectors, when adoptively transferred to mice bearing a platinum resistant tumor cell line, were capable of controlling tumor growth. These data support future translation of this vaccine strategy into human clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2012
- Accession Number
- ADA567830
Entities
People
- Michael A. Morse
Organizations
- Duke University